The expression of phosphatidylinositol 3 kinase (PIK3CG) was upregulated when bevacizumab treated RPE cells in an AMD model [41], suggesting that PIK3CG may be a target for the treatment of AMD. Here, PIK3CG is linked to age-related macular degeneration.